Moerland, J. A., Zhang, D., Reich, L. A., Carapellucci, S., Lockwood, B., Leal, A. S., . . . Liby, K. T. (2020). The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Nature Portfolio.
Chicago Style (17th ed.) CitationMoerland, Jessica A., et al. The Novel Rexinoid MSU-42011 Is Effective for the Treatment of Preclinical Kras-driven Lung Cancer. Nature Portfolio, 2020.
MLA (8th ed.) CitationMoerland, Jessica A., et al. The Novel Rexinoid MSU-42011 Is Effective for the Treatment of Preclinical Kras-driven Lung Cancer. Nature Portfolio, 2020.
Warning: These citations may not always be 100% accurate.